WuXi Biology Launches FREE DELopen Gen5 Kit with Dual-Library Power：
Small Molecule + Peptide DEL for Academia!
WuXi Biology is pleased to introduce DELopen 5th Generation Screening Kit, with upgraded DNA-encoded libraries containing 6.3 billion unique small molecules and 0.27 billion distinct peptides. The enhanced small molecule libraries feature a 50% increase in compound diversity, while the newly integrated peptide libraries include both linear and cyclic peptides. This kit is designed to empower drug discovery for academia users by enabling high-throughput exploration of vast chemical space and advancing novel therapeutic modalities.
Try for free with your purified target protein!
In addition, we provide a variety of services that can be tailored to your needs:
✅ Free kit access
✅ Free post-selection processing, sequencing, and data analysis
✅ Screening by our expert team (request a quote)
✅ Hit validation through affinity selection-mass spectrometry (request a quote)
For a limited time, we’re offering discounts on your downstream services for new projects (terms and conditions may apply):
✅ 10% off for samples returned by June 1, 2026
✅ 10% off for screening service contract by June 1, 2026
✅ 5% off for referring new labs by September 1, 2026
More about DELopen:
DNA-encoded library (DEL) is a technology that enables fast screening of billions of molecules in the early phase of drug discovery. DELopen provides free access to DEL for academic users and encourages an open, community-based approach to data sharing. DELopen users can conduct affinity-selection experiments in their own labs using free DELopen libraries, and WuXi Biology will provide post-selection processing, sequencing, and data analysis at no cost. If promising hits are identified and validated, users can choose data exchange for the disclosure of chemical structures.
The DELopen platform has become an indispensable tool for academic researchers worldwide for drug discovery. This screening platform has empowered over 500 academic research groups globally to perform successful DEL screens with DELopen, directly contributing to the publication of more than 20 high-impact scientific papers and accelerating drug discovery across diverse therapeutic areas.
